Black Diamond Therapeutics vs Sutro Biopharma
BDTX and STRO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and STRO compare
Sutro Biopharma is the larger company, worth 1.8 times as much as Black Diamond Therapeutics ($170M against $92.5M).
Sutro Biopharma grew revenue faster over the last twelve months (−56.3% versus −100% for Black Diamond Therapeutics).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | STRO |
|---|---|---|
| Size and price | ||
| Market cap | $92.5M | $170M |
| Share price | $1.61 | $10.26 |
| Change, 1 year | −63.1% | 27.3% |
| Change, 5 years | −77.3% | −94.2% |
| Beta (5Y) | 2.49 | 2.21 |
| Employees | 21 | 137 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 3.7× |
| P/B | 1.1× | – |
| Growth | ||
| Revenue growth (TTM) | −100% | −56.3% (better) |
| Revenue growth, 5Y average | – | 19.1% |
| Net income growth (TTM) | −305% | – |
| EPS growth (TTM) | −311% | – |
| Profitability | ||
| Operating margin | – | −320% |
| Net margin | – | −395% |
| Return on equity | −41.1% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 6.92 (better) | 3.32 |
| Altman Z-score | −4.53 (better) | −8.74 |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 99.4% |
| Held by insiders | 9.1% | 6.1% |
| Insider net buying, 12 months | – | $0 |
| Short interest, % of float | 9.8% | 14.5% |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- STRO stock overview
- STRO income statement
- STRO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.